{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T10:13:52Z","timestamp":1792059232319,"version":"4.4.0"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Urology"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1016\/j.juro.2012.01.125","type":"journal-article","created":{"date-parts":[[2012,4,12]],"date-time":"2012-04-12T19:15:09Z","timestamp":1334258109000},"page":"2131-2139","source":"Crossref","is-referenced-by-count":300,"title":["Phase 3 Efficacy and Tolerability Study of OnabotulinumtoxinA for Urinary Incontinence From Neurogenic Detrusor Overactivity"],"prefix":"10.1097","volume":"187","author":[{"given":"David","family":"Ginsberg","sequence":"first","affiliation":[{"name":"University of Southern California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Gousse","sequence":"additional","affiliation":[{"name":"Herbert Wertheim College of Medicine, Florida International University, Miami, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronique","family":"Keppenne","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Li\u00e8ge, Liege, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl-Dietrich","family":"Sievert","sequence":"additional","affiliation":[{"name":"University of Tuebingen, Tuebingen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Thompson","sequence":"additional","affiliation":[{"name":"Allergan, Inc., Irvine, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne","family":"Lam","sequence":"additional","affiliation":[{"name":"Allergan, Inc., Irvine, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell F.","family":"Brin","sequence":"additional","affiliation":[{"name":"University of California-Irvine, Irvine, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"Jenkins","sequence":"additional","affiliation":[{"name":"Allergan, Inc., Irvine, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia","family":"Haag-Molkenteller","sequence":"additional","affiliation":[{"name":"Allergan, Inc., Irvine, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"10.1016\/j.juro.2012.01.125_bib1","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nrn2401","article-title":"The neural control of micturition","volume":"9","author":"Fowler","year":"2008","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.juro.2012.01.125_bib2","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1097\/01.phm.0000219229.92056.c2","article-title":"Pharmacotherapy for neurogenic detrusor overactivity","volume":"85","author":"Chancellor","year":"2006","journal-title":"Am J Phys Med Rehabil"},{"key":"10.1016\/j.juro.2012.01.125_bib3","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.eururo.2009.04.028","article-title":"EAU guidelines on neurogenic lower urinary tract dysfunction","volume":"56","author":"Stohrer","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2012.01.125_bib4","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1046\/j.1464-410X.1997.00191.x","article-title":"Vesico-ureteric reflux in adult patients with spinal injury","volume":"79","author":"Foley","year":"1997","journal-title":"Br J Urol"},{"key":"10.1016\/j.juro.2012.01.125_bib5","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s11136-010-9590-z","article-title":"Exploring the impact of changes in neurogenic urinary incontinence frequency and condition-specific quality of life on preference-based outcomes","volume":"19","author":"Hollingworth","year":"2010","journal-title":"Qual Life Res"},{"key":"10.1016\/j.juro.2012.01.125_bib6","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.eururo.2007.04.026","article-title":"Botulinum toxin A improves the quality of life of patients with neurogenic urinary incontinence","volume":"52","author":"Schurch","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2012.01.125_bib7","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.apmr.2007.02.009","article-title":"Reliability and validity of the Incontinence Quality of Life questionnaire in patients with neurogenic urinary incontinence","volume":"88","author":"Schurch","year":"2007","journal-title":"Arch Phys Med Rehabil"},{"key":"10.1016\/j.juro.2012.01.125_bib8","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s00404-010-1720-x","article-title":"Anticholinergic therapy: do the patients take the pills prescribed?","volume":"284","author":"Jundt","year":"2011","journal-title":"Arch Gynecol Obstet"},{"key":"10.1016\/j.juro.2012.01.125_bib9","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2165\/00003495-200363020-00003","article-title":"Bladder, bowel and sexual dysfunction in multiple sclerosis: management strategies","volume":"63","author":"DasGupta","year":"2003","journal-title":"Drugs"},{"key":"10.1016\/j.juro.2012.01.125_bib10","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/ptj\/82.6.601","article-title":"Neurogenic bladder, neurogenic bowel, and sexual dysfunction in people with spinal cord injury","volume":"82","author":"Benevento","year":"2002","journal-title":"Phys Ther"},{"key":"10.1016\/j.juro.2012.01.125_bib11","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/S0022-5347(05)67283-7","article-title":"Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results","volume":"164","author":"Schurch","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2012.01.125_bib12","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/01.ju.0000162035.73977.1c","article-title":"Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study","volume":"174","author":"Schurch","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2012.01.125_bib13","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0090-4295(98)00454-3","article-title":"Quality of life of women with urinary incontinence: further development of the incontinence quality of life instrument (I-QOL)","volume":"53","author":"Patrick","year":"1999","journal-title":"Urology"},{"key":"10.1016\/j.juro.2012.01.125_bib14","series-title":"Therapy with Botulinum Toxin","first-page":"93","article-title":"Immunogenicity of the neurotoxins of Clostridium botulinum","author":"Hatheway","year":"1994"},{"key":"10.1016\/j.juro.2012.01.125_bib15","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.eururo.2007.10.013","article-title":"Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity\/neurogenic overactive bladder: a systematic literature review","volume":"53","author":"Karsenty","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2012.01.125_bib16","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.eururo.2011.07.002","article-title":"Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomized, double-blind, placebo-controlled trial","volume":"60","author":"Cruz","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2012.01.125_bib17","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1212\/WNL.45.7.1268","article-title":"Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial","volume":"45","author":"Johnson","year":"1995","journal-title":"Neurology"},{"key":"10.1016\/j.juro.2012.01.125_bib18","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1212\/WNL.0b013e318205051d","article-title":"Long-term follow-up of clinical trials of multiple sclerosis therapies","volume":"76","author":"Freedman","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.juro.2012.01.125_bib19","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/nau.21003","article-title":"Epidemiology and healthcare utilization of neurogenic bladder patients in a US claims database","volume":"30","author":"Manack","year":"2011","journal-title":"Neurourol Urodyn"}],"container-title":["Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022534712002613?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022534712002613?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.jurology.com\/doi\/pdf\/10.1016\/j.juro.2012.01.125","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T02:21:52Z","timestamp":1651198912000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jurology.com\/doi\/10.1016\/j.juro.2012.01.125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["10.1016\/j.juro.2012.01.125"],"URL":"https:\/\/doi.org\/10.1016\/j.juro.2012.01.125","relation":{},"ISSN":["0022-5347","1527-3792"],"issn-type":[{"value":"0022-5347","type":"print"},{"value":"1527-3792","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6]]}}}